Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Schleich (Liege, Belgium), G. Brusselle (Ghent, Belgium), S. Hanon (Bruxelles, Belgium), O. Vandenplas (Yvoir, Belgium), L. Dupont (Leuven, Belgium), R. Peche (Charleroi, Belgium), A. Michils (Bruxelles, Belgium), C. Pilette (Bruxelles, Belgium), O. Michel (Bruxelles, Belgium), S. Graff (Liege, Belgium), H. Nekoee (Liege, Belgium), A. Donneau (Liege, Belgium), J. Halloy (Baudur, Belgium), V. Dufresne (Gosselies, Belgium), J. Noel (Ottignies, Belgium), L. Vandezande (Bouge, Belgium), G. Joos (Ghent, Belgium), R. Louis (Liege, Belgium). Characteristics of severe asthmatics treated with omalizumab, mepolizumab or no biotherapy. Data from the Belgian Severe Asthma Registry (BSAR).. 5353

Member's Comments

No comment yet.

Related content which might interest you: COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry Source: Eur Respir J, 56 (6) 2002857; 10.1183/13993003.02857-2020 Year: 2020 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Chronic oral corticosteroids use and persistent eosinophilia in severe asthma. The Belgian Severe Asthma Registry. Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Triple combination therapy in severe asthma: overview from the Italian Registry Severe Asthma (IRSA) Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Asthma control is reached in a large majority of asthmatics treated with omalizumab. An Italian observational study Source: Annual Congress 2013 –Disease control and quality of life in airway diseases Year: 2013 Outcomes with omalizumab in Indian patients with allergic (IgE-mediated) asthma: Results at 16 and 28 weeks Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Impact of bronchiectasis on severe asthma: data from the “Severe Asthma Network Italy” (SANI) registry Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Proportion of complete responders after one year of treatment with biologics for severe asthma - Results from the nationwide Danish Severe Asthma Register. Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013 Clinical experience with montelukast plus ICS vs. only ICS in non-asthmatic eosinophilic bronchitis (NAEB) in Indian patients Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Clinical profile and treatment of elderly patients hospitalized for acute exacerbation of asthma . A comparative study Source: International Congress 2014 – Asthma: clinical problems Year: 2014 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014